keyword
MENU ▼
Read by QxMD icon Read
search

allogeneic hematopoietic cell transplantation

keyword
https://www.readbyqxmd.com/read/28926431/epigenetic-regulation-of-dendritic-cell-development-and-function
#1
Yuanyuan Tian, Lijun Meng, Yi Zhang
The immune system is characterized by the generation of structurally and functionally heterogeneous immune cells that constitute complex innate and adaptive immunity. This heterogeneity of immune cells results from changes in the expression of genes without altering DNA sequence. To achieve this heterogeneity, immune cells orchestrate the expression and functional status of transcription factor (TF) networks, which can be broadly categorized into 3 classes: pioneer TFs that facilitate initial commitment and differentiation of hematopoietic cells, subset-specific TFs that promote the generation of selected cell lineages, and immune-signaling TFs that regulate specialized function in differentiated cells...
September 2017: Cancer Journal
https://www.readbyqxmd.com/read/28926288/effect-of-inpatient-palliative-care-during-hematopoietic-stem-cell-transplant-on-psychological-distress-6-months-after-transplant-results-of-a-randomized-clinical-trial
#2
Areej El-Jawahri, Lara Traeger, Joseph A Greer, Harry VanDusen, Sarah R Fishman, Thomas W LeBlanc, William F Pirl, Vicki A Jackson, Jason Telles, Alison Rhodes, Zhigang Li, Thomas R Spitzer, Steven McAfee, Yi-Bin A Chen, Jennifer S Temel
Purpose Inpatient palliative care integrated with transplant care improves patients' quality of life (QOL) and symptom burden during hematopoietic stem-cell transplant (HCT). We assessed patients' mood, post-traumatic stress disorder (PTSD) symptoms, and QOL 6 months post-transplant. Methods We randomly assigned 160 patients with hematologic malignancies who underwent autologous or allogeneic HCT to inpatient palliative care integrated with transplant care (n = 81) or transplant care alone (n = 79). At baseline and 6 months post-transplant, we assessed mood, PTSD symptoms, and QOL with the Hospital Anxiety and Depression Scale and Patient Health Questionnaire, PTSD checklist, and Functional Assessment of Cancer Therapy-Bone Marrow Transplant...
September 19, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28923646/usefulness-of-post-transplant-hematopoietic-chimera-monitoring-by-use-of-the-quantitative-fluorescence-polymerase-chain-reaction-method
#3
M Lejman, K Drabko, B Styka, D Winnicka, M Babicz, I Jaszczuk, J R Kowalczyk
BACKGROUND: In the light of an increasing number of hematopoietic stem cell transplantations and more frequent use of reduced-intensity conditioning as preparative regimens for hematopoietic stem cell transplantation, post-transplant cell chimera monitoring is considered a necessity. METHODS: The quantitative fluorescence polymerase chain reaction method, along with the commercial AmpFSTR SGMPlus kit, was applied in research on hematopoietic chimeras. RESULTS: The total of 102 patients who had undergone allogenic transplantations were investigated...
October 2017: Transplantation Proceedings
https://www.readbyqxmd.com/read/28921816/comprehensive-genetic-analysis-of-donor-cell-derived-leukemia-with-kmt2a-rearrangement
#4
Rieko Taniguchi, Hideki Muramatsu, Yusuke Okuno, Kyogo Suzuki, Satoshi Obu, Masahiro Nakatochi, Teppei Shimamura, Yoshiyuki Takahashi, Yasuo Horikoshi, Kenichiro Watanabe, Seiji Kojima
BACKGROUND: Donor cell leukemia (DCL) occurs after allogeneic hematopoietic stem cell transplantation. Several mechanisms, including occult leukemic/preleukemic subclones in the donor graft and germline predisposition to leukemia, are proposed to be associated with DCL's molecular pathogenesis. We report a comprehensive genetic analysis of a patient with KMT2A-rearranged DCL after allogeneic bone marrow transplantation for refractory cytopenia of childhood. PROCEDURE: We performed a whole-exome sequencing of the recipient's peripheral blood before transplant and the donor's peripheral blood and the recipient's bone marrow at the time of DCL diagnosis...
September 17, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28921804/early-blood-stream-infection-following-allogeneic-hematopoietic-stem-cell-transplantation-is-a-risk-factor-for-acute-grade-iii-iv-gvhd-in-children-and-adolescents
#5
Hirozumi Sano, Joseph A Hilinski, Muna Qayed, Kristy Applegate, Joanna G Newton, Benjamin Watkins, Kuang-Yueh Chiang, John Horan
BACKGROUND: Graft-versus-host disease (GVHD) remains a major cause of mortality and morbidity in allogeneic hematopoietic stem cell transplantation (HSCT). In adults, early blood stream infection (BSI) and acute GVHD (AGVHD) have been reported to be related. The impact of BSI on risk for AGVHD, however, has not been assessed in pediatric patients. PROCEDURE: We conducted a retrospective analysis to test the hypothesis that early BSI (before day +30) predisposes allogeneic pediatric transplant patients to severe AGVHD...
September 17, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28921764/acanthamoeba-granulomatous-amoebic-encephalitis-after-pediatric-hematopoietic-stem-cell-transplant
#6
Scott L Coven, Eunkyung Song, Sarah Steward, Christopher R Pierson, Jennifer R Cope, Ibne K Ali, Monica I Ardura, Mark W Hall, Melissa G Chung, Rajinder P S Bajwa
Acanthamoeba encephalitis is a rare, often fatal condition, particularly after HSCT, with 9 reported cases to date in the world literature. Our case was originally diagnosed with ALL at age 3 years, and after several relapses underwent HSCT at age 9 years. At 17 years of age, he was diagnosed with secondary AML for which he underwent a second allogeneic HSCT. He presented with acute-onset worsening neurological deficits on day +226 after the second transplant and a post-mortem diagnosis of Acanthamoeba encephalitis was established, with the aid of the CDC...
September 17, 2017: Pediatric Transplantation
https://www.readbyqxmd.com/read/28921749/functional-specific-t-cell-expansion-after-first-cytomegalovirus-reactivation-predicts-viremia-control-in-allogeneic-hematopoietic-stem-cell-transplant-recipients
#7
Miriam Ciáurriz, Lorea Beloki, Amaya Zabalza, Eva Bandrés, Cristina Mansilla, Estela Pérez-Valderrama, Mercedes Lachén, Mercedes Rodríguez-Calvillo, Natalia Ramírez, Eduardo Olavarría
BACKGROUND: The use of preemptive antiviral therapy to prevent cytomegalovirus (CMV) disease in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients might result in over-treatment, inducing drug-related toxicity and viral resistance. A search for predictive markers is needed, to determine requirement for antiviral therapy. Clinical follow-up, in combination with the use of streptamers (STs) and cytokine-intracellular staining, could help to identify patients at high risk for CMV reactivations...
September 16, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/28905389/the-first-reported-case-of-concurrent-trimethoprim-sulfamethoxazole-induced-immune-hemolytic-anemia-and-thrombocytopenia
#8
Yevgeniy A Linnik, Edison W Tsui, Isabella W Martin, Zbigniew M Szczepiorkowski, Gregory A Denomme, Jerome L Gottschall, John M Hill, Nancy M Dunbar
BACKGROUND: Drug-induced immune hemolytic anemia (DIIHA) and drug-induced immune thrombocytopenia (DIIT) are rare but dangerous complications of pharmacotherapy that may be underrecognized in hematopoietic stem cell transplant (HSCT) patients due to overlap of signs and symptoms with those of more common disease processes. CASE REPORT: A 61-year-old woman with NK-cell deficiency and GATA-2-associated myelodysplastic syndrome, status post-recent allogeneic HSCT (Day +58), presented with 3 days of acute-onset severe back pain, muscle cramps, and increasingly dark urine...
September 14, 2017: Transfusion
https://www.readbyqxmd.com/read/28900828/everyday-life-following-hematopoietic-stem-cell-transplantation-decline-in-physical-symptoms-within-the-first-month-and-change-related-predictors
#9
Aleksandra Kroemeke, Małgorzata Sobczyk-Kruszelnicka, Zuzanna Kwissa-Gajewska
PURPOSE: Lower quality of life, especially in the physical domain (Physical-QOL), is common in patients after hematopoietic stem cell transplantation (HSCT). However, few studies explore changes in the Physical-QOL, i.e., physical symptoms, in everyday life of patients following HSCT. The present study addresses this gap by examining patient daily physical symptoms and their predictors in terms of demographic and clinical characteristics. METHODS: Physical symptoms were reported by 188 patients (56...
September 12, 2017: Quality of Life Research
https://www.readbyqxmd.com/read/28900606/lymphocyte-recovery-is-an-independent-predictor-of-relapse-in-allogeneic-hematopoietic-cell-transplantation-recipients-for-acute-leukemia
#10
Moussab Damlaj, Samer Ghazi, Walid Mashaqbeh, Gamal Gmati, Hend Salama, Khadega A Abuelgasim, Mushtaq Rather, Ali Hajeer, Mohsen Al-Zahrani, Abdul-Rahman Jazieh, Ayman Alhejazi, Ahmed Alaskar
AIM: To examine the optimal absolute lymphocyte count (ALC) cut-off utilizing receiver operator characteristics (ROC) in addition to graft characteristics associated with early ALC recovery. METHODS: Patients who received T-cell replete peripheral hematopoietic cell transplantation (HCT) for acute leukemia were identified. ALC cut-off was established using ROC analysis and subsequently the cohort was stratified. Time to endpoint analysis and cox regression modelling was computed to analyze outcomes...
August 24, 2017: World Journal of Transplantation
https://www.readbyqxmd.com/read/28893518/curative-approaches-for-sickle-cell-disease-a-review-of-allogeneic-and-autologous-strategies
#11
Daniel E Bauer, Christian Brendel, Courtney D Fitzhugh
Despite sickle cell disease (SCD) first being reported >100years ago and molecularly characterized >50years ago, patients continue to experience severe morbidity and early mortality. Although there have been substantial clinical advances with immunizations, penicillin prophylaxis, hydroxyurea treatment, and transfusion therapy, the only cure that can be offered is hematopoietic stem cell transplantation (HSCT). In this work, we summarize the various allogeneic curative approaches reported to date and discuss open and upcoming clinical research protocols...
September 1, 2017: Blood Cells, Molecules & Diseases
https://www.readbyqxmd.com/read/28892086/allogeneic-stem-cell-transplantation-and-subsequent-treatments-as-a-comprehensive-strategy-for-long-term-survival-of-multiple-myeloma-patients
#12
V Montefusco, A Mussetti, F Rezzonico, F Maura, M Pennisi, C de Philippis, M Capecchi, P Corradini
We evaluated 71 patients treated with allogeneic hematopoietic cell transplantation (allo-HCT) for multiple myeloma (MM). Forty-three patients (61%) received allo-HCT after the first line of therapy. Fifty-eight patients (82%) had chemosensitive disease at the time of allo-HCT. A HLA-matched related or unrelated donor was available for 68 patients (96%). Non-myeloablative or reduced-intensity conditioning regimen and peripheral blood hematopoietic cells as a graft source were used in most patients. The cumulative incidence of grade II-IV acute GVHD at day +100 and chronic GVHD at 5 years was 13% (95% CI 7-23%) and 35% (95% CI 24-46), respectively...
September 11, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28892085/circulating-endothelial-cell-count-a-reliable-marker-of-endothelial-damage-in-patients-undergoing-hematopoietic-stem-cell-transplantation
#13
C Almici, C Skert, B Bruno, A Bianchetti, R Verardi, A Di Palma, A Neva, S Braga, G Piccinelli, G Piovani, M Malagola, S Bernardi, L Giaccone, L Brunello, M Festuccia, K Baeten, D Russo, M Marini
The physio-pathologic interrelationships between endothelium and GvHD have been better elucidated and have led to definition of the entity 'endothelial GvHD' as an essential early phase prior to the clinical presentation of acute GvHD. Using the CellSearch system, we analyzed circulating endothelial cells (CEC) in 90 allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients at the following time-points: T1 (pre-conditioning), T2 (pre-transplant), T3 (engraftment), T4 (onset of GvHD) and T5 (1 week after steroid treatment)...
September 11, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28890406/comparison-of-conditioning-with-fludarabine-busulfan-and-fludarabine-melphalan-in-allogeneic-transplant-recipients-50-years-or-older
#14
Koji Kawamura, Shinichi Kako, Shuichi Mizuta, Ken Ishiyama, Jun Aoki, Shingo Yano, Takahiro Fukuda, Naoyuki Uchida, Yukiyasu Ozawa, Tetsuya Eto, Koji Iwato, Heiwa Kanamori, Kaoru Kahata, Tadakazu Kondo, Masashi Sawa, Tatsuo Ichinohe, Yoshiko Atsuta, Yoshinobu Kanda
The optimal conditioning regimen for elderly patients in allogeneic hematopoietic stem cell transplantation (allo-HCT) remains unclear. We retrospectively analyzed 1607 patients aged 50 years or older with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or myelodysplastic syndrome (MDS) who underwent allo-HCT using fludarabine/busulfan (FB) or fludarabine/melphalan (FM) between 2007 and 2014. We compared the clinical outcomes among FB2 (busulfan at 6.4 mg/kg iv, n=463), FB4 (busulfan at 12...
September 7, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28890263/-secondary-thrombotic-microangiopathies
#15
P Coppo
Thrombotic microangiopathies (TMA) are termed secondary when associated to a specific context favouring their occurrence. They encompass mainly TMA associated with pregnancy, allogeneic hematopoietic stem cell transplantation, cancer, drugs, or HIV infection. Secondary TMA represent a heterogeneous group of diseases which clinical presentation largely depends on the associated context. It is therefore mandatory to recognize these conditions since they have a significant impact in TMA management and prognosis...
September 7, 2017: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/28889862/genetic-dna-profile-in-urine-and-hair-follicles-from-patients-who-have-undergone-allogeneic-hematopoietic-stem-cell-transplantation
#16
Ana Santurtún, José A Riancho, Maite Santurtún, Carlos Richard, M Mercedes Colorado, Mayte García Unzueta, María T Zarrabeitia
Biological samples from patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT) constitute a challenge for individual identification. In this study we analyzed the genetic profiles (by the amplification of 15 autosomic STRs) of HSCT patients found in different types of samples (blood, hair and urine) that may be the source of DNA in civil or criminal forensic cases. Our results show that while in hair follicles the donor component was not detected in any patient, thus being a reliable source of biological material for forensic identification, mixed chimerism was detected in urine samples from all patient, and no correlation was found between the time elapsed from the transplant and the percentage of chimerism...
September 2017: Science & Justice: Journal of the Forensic Science Society
https://www.readbyqxmd.com/read/28888028/effect-of-reduced-intensity-conditioning-and-the-risk-of-late-onset-non-infectious-pulmonary-complications-in-pediatric-patients
#17
Masayuki Nagasawa, Noriko Mitsuiki, Yuki Aoki, Toshiaki Ono, Takeshi Isoda, Kohsuke Imai, Masatoshi Takagi, Michiko Kajiwara, Hirokazu Kanegane, Tomohiro Morio
OBJECTIVE: Late-onset non-infectious pulmonary complications (LONIPCs) contribute to higher morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Therefore, we investigated the risk factors of LONIPCs in pediatric patients. METHOD: Between 2001 and 2011, 74 pediatric patients (range, 7 months to 22.7 years old; median 6.5 years old), including 29 with a primary immunodeficiency underwent 80 allo-HSCTs at our institution. Sixty-seven patients who survived more than 3 months after allo-HSCT were analyzed retrospectively...
September 9, 2017: European Journal of Haematology
https://www.readbyqxmd.com/read/28887325/at-least-20-donor-myeloid-chimerism-is-necessary-to-reverse-the-sickle-phenotype-after-allogeneic-hsct
#18
Courtney D Fitzhugh, Stefan Cordes, Tiffani Taylor, Wynona Coles, Katherine Roskom, Mary Link, Matthew M Hsieh, John F Tisdale
Novel curative therapies employing genetic transfer of normal globin-producing genes into autologous hematopoietic stem cells (HSCs) are in clinical trials for patients with sickle cell disease (SCD). The percentage of transferred globin necessary to cure SCD is currently not known. In the setting of allogeneic nonmyeloablative hematopoietic stem cell transplants (HSCT), stable mixed chimerism is sufficient to reverse the disease. We regularly monitored 67 patients after HSCT. After initially robust engraftment, three of these patients experienced declining donor myeloid chimerism (DMC) levels with eventual return of disease...
September 8, 2017: Blood
https://www.readbyqxmd.com/read/28883081/haploidentical-hematopoietic-cell-transplantation-for-adult-acute-myeloid-leukemia-a-position-statement-from-the-acute-leukemia-working-party-of-the-european-society-for-blood-and-marrow-transplantation
#19
Catherine J Lee, Bipin N Savani, Mohamad Mohty, Myriam Labopin, Annalisa Ruggeri, Christoph Schmid, Frédéric Baron, Jordi Esteve, Norbert C Gorin, Sebastian Giebel, Fabio Ciceri, Arnon Nagler
Allogeneic blood or marrow hematopoietic cell transplantation continues to be the most potent anti-leukemic treatment for adult patients with standard or high-risk, or chemo-refractory acute myeloid leukemia. Until recently, this procedure was generally limited to those recipients who had an available matched-sibling donor or matched-unrelated donor. Technical advances in graft cell processing and manipulation, control of bidirectional T cell alloreactivity, graft-versus-host disease prophylaxis, and other supportive measures in haploidentical transplantation now enables nearly all patients with acute myeloid leukemia to benefit from the graft-versus-leukemia effect with substantial reduction in procedure-related mortality...
September 7, 2017: Haematologica
https://www.readbyqxmd.com/read/28882882/how-i-treat-patients-with-hiv-related-hematological-malignancies-using-hematopoietic-cell-transplantation
#20
Joseph C Alvarnas, John A Zaia, Stephen J Forman
Hematopoietic cell transplantation (HCT) has now been shown to be safe and effective for selected HIV-infected patients with hematological malignancies. Autologous HCT is now standard of care for patients with HIV-related lymphomas who otherwise meet standard transplant criteria. Limited data also supports use of allogeneic HCT (alloHCT) in selected HIV-infected patients who meet standard transplant criteria. We recommend enrolling patients on clinical trials that offer access to CCR5Δ32 homozygous donors, if available...
September 7, 2017: Blood
keyword
keyword
120477
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"